Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome.
- Published In:
- Medical hypotheses, 68(5), 1144-6 (2007)
- Authors:
- Tsai, Shih-Jen
- Database ID:
- RPEP-01297
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01297APA
Tsai, Shih-Jen. (2007). Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome.. Medical hypotheses, 68(5), 1144-6.
MLA
Tsai, Shih-Jen. "Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome.." Medical hypotheses, 2007.
RethinkPeptides
RethinkPeptides Research Database. "Semax, an analogue of adrenocorticotropin (4-10), is a poten..." RPEP-01297. Retrieved from https://rethinkpeptides.com/research/tsai-2007-semax-an-analogue-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.